The Blue Book Released

RDC Sector Gains Momentum as Radiopharma Develops China's First Independently Researched Class 1 Radiopharmaceutical

Radiopharmaceutical Conjugate (RDC) drugs are a cutting-edge and innovative treatment form that combines targeting vectors with radionuclides. These innovative medicines use molecular carriers specific to tumor antigens to deliver radionuclides, enabling precise targeting of tumors for internal radiotherapy or diagnostic purposes. Radiopharma, as an innovative leader in providing comprehensive molecular imaging and diagnostic solutions in nuclear medicine, has harnessed years of extensive research in this field. The company has developed groundbreaking products in both radiopharmaceuticals and nuclear medical imaging devices. Its research pipeline covers multiple areas, including SPECT diagnostic drugs, PET diagnostic drugs, targeted radiotherapeutic drugs, and advanced imaging equipment.

In the radiopharmaceutical sector, Radiopharma has achieved a significant milestone with the development of China's first independently researched Class 1 nuclear medicine drug, 99mTc-3PRGD2 (Technetium [99mTc] Hydrazinonicotinamide Polyethylene Glycol Dimeric RGD Peptide Injection). This drug is the world's first broad-spectrum tumor imaging agent designed for SPECT imaging diagnostics. It revolutionizes the application of SPECT/CT imaging technology in tumor diagnosis, staging, and treatment evaluation, providing an innovative solution for early tumor detection. Currently, the drug is undergoing the marketing approval process and has been granted priority review by the Center for Drug Evaluation (CDE). Once approved, it is expected to significantly reduce the costs of clinical tumor examinations and enhance diagnostic accessibility.

Embracing a philosophy akin to "integration of pharmaceuticals and devices," Radiopharma is also advancing the development of high-sensitivity SPECT/CT equipment. This state-of-the-art technology aims to improve imaging resolution and dramatically shorten examination times, thereby enhancing the overall efficiency and accuracy of nuclear medicine diagnostics.

Rabpharma Explores Groundbreaking Therapies in Bone Regeneration

Peptide Drug Conjugates (PDCs) are emerging as a promising class of drugs with extensive clinical potential. Compared to Antibody Drug Conjugates (ADCs), PDCs offer higher tumor penetration and lower immunogenicity, significantly reducing off-target toxicity. This opens up new possibilities not only for targeted cancer therapy but also for treating inflammation and drug-resistant viral and bacterial targets.

Featured in the latest Blue Book, Rabpharma—a Baheal Investment company—specializes in developing innovative treatments for challenging orthopedic conditions. The company has built robust PDC conjugation and high-throughput screening platforms. Rabpharma's flagship product, RAB-001, is the world’s first peptide drug conjugate targeting non-traumatic osteonecrosis. By inducing mesenchymal stem cells to migrate into bone tissue, RAB-001 promotes both bone and vascular regeneration, offering new hope for patients with osteonecrosis. Having completed Phase I clinical trials in the United States and received CDE clinical approval in China, RAB-001 is currently undergoing Phase II trials. Moreover, Rabpharma has several other products in preclinical development targeting bone and joint diseases.

The Blue Book forecasts a promising future for the conjugated drug industry, driven by technological advancements and expanded clinical applications. The continuous emergence of new targets, linkers, and conjugation technologies will create more possibilities for drug development. Likewise, the rising global cancer incidence and increasing demand for high-quality treatments are expected to spur significant market growth.

Against this backdrop, Baheal Pharma Group is committed to its mission of "optimizing medical scenarios through technological innovation." The company leverages a comprehensive innovation incubation system covering the entire industry chain, from initial breakthroughs to commercialization. Baheal Pharmal (301015.SZ), a listed subsidiary, has already secured exclusive commercialization rights for relevant products through partnerships with Radiopharma and Rabpharma. These collaborations aim to expedite the clinical application of these cutting-edge treatments.

As biopharmaceutical innovation enters a new phase of rapid advancement, Baheal Pharma remains dedicated to addressing real-world clinical needs. Utilizing the collaborative strengths of its "Eco-friendly Big Pharma" resources, Baheal is committed to accelerating the translation and commercialization of pioneering technologies. This ongoing effort aims to offer patients a broader array of high-quality diagnostic and therapeutic options.